Centre Hospitalier Universitaire de Saint-Étienne (CHU)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials (2024) Peyrin‐Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola , Jahnsen J, et al. Journal article Expansion of the neurodevelopmental phenotype of individuals with EEF1A2 variants and genotype-phenotype study (2024) Paulet A, Bennett-Ness C, Ageorges F, Trost D, Green A, Goudie D, Jewell R, et al. Journal article Correction to: Expansion of the neurodevelopmental phenotype of individuals with EEF1A2 variants and genotype-phenotype study (European Journal of Human Genetics, (2024), 10.1038/s41431-024-01560-8) (2024) Paulet A, Bennett-Ness C, Ageorges F, Trost D, Green A, Goudie D, Jewell R, et al. Journal article, Erratum Bi-allelic loss-of-function variants in PPFIBP1 cause a neurodevelopmental disorder with microcephaly, epilepsy, and periventricular calcifications (2022) Rosenhahn E, O'Brien TJ, Zaki MS, Sorge I, Wieczorek D, Rostasy K, Vitobello A, et al. Journal article Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, et al. Journal article, Review article A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy (2022) Baert FJ, Atreya R, Kakuta Y, Long M, Roblin X, Neimark E, Song A, et al. Conference contribution A mathematical model to estimate the number of unreported SARS-CoV-2 infections in the early phase of the pandemic using Germany and Italy as examples Ein mathematisches Modell zur Schätzung der Dunkelziffer von SARS-CoV-2-Infektionen in der Frühphase der Pandemie am Beispiel Deutschland und Italien (2021) Fiedler J, Moritz CP, Feth S, Speckert M, Dressler K, Schoebel A Journal article Pediatric Mesothelioma Tumors: The European Expert Group Contribution (2020) Orbach D, Andre N, Brecht I, Lopez Almaraz R, Ben Ami T, Wermersch S, Carton M, et al. Conference contribution Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. (2020) De Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D'Amato L, et al. Journal article